Bifogade filer
Lipum AB – Bokslutskommunike 2024
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Lipum AB (publ) has published the Q4 interim and year-end report for 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website.
Financial summary January – December 2024
- Other operating income: 911 KSEK (165)
- Result after financial items: -55 516 KSEK (-37 178)
- Cash and cash equivalents as of December 31: 6 632 KSEK (10 226)
Significant events during the period October to December 2024
- Lipum Presents Promising Data on Novel Antibody SOL-116 at ACR 2024.
- Lipum and Age Labs have been granted funding from Eurostars.
Significant events after the period
- Lipum has successfully completed the phase I study with SOL-116.
CEO Ola Sandborgh comments – “Excellent results paving the way for Phase II”
My first year as CEO of Lipum has been an incredible journey filled with inspiring challenges, excellent results, and execution according to plan - setting the stage for an exciting future. Over the past year, we have successfully enrolled all subjects and patients in our Phase I study, and we are now able to present the first results. Stepping in as the new CEO of Lipum has meant long and intense days ensuring that every piece falls into place. I would also like to extend a special thanks to my predecessor, Einar Pontén, and the entire team for laying a solid foundation, enabling us to advance SOL-116 toward our goal of offering a treatment that alleviates painful symptoms and improves the quality of life for millions of patients suffering from chronic inflammatory diseases.
In our Phase I study, we primarily evaluated the safety and tolerability of SOL-116 in 48 healthy volunteers and 8 patients with rheumatoid arthritis (RA). The final results confirm a reassuring safety profile with no cases of serious adverse events, predictable pharmacokinetics, and minimal development of anti-drug antibodies (ADA). Additionally, we observed high specificity for the target protein BSSL (bile salt-stimulated lipase), with an immediate reduction to undetectable levels in the blood. These excellent results provide us with strong support and confidence as we move forward to the next step: a Phase II study
Ola Sandborgh, CEO
CEO Ola Sandborgh and CMO Peter Hovstadius will comment on the study results during the presentation of the Q4 Interim Report and Year-End Report 2024 in a live webcast on 26 February 2025, 9 am CET (in Swedish only).
The complete report (only in Swedish) is available at www.lipum.se